127 related articles for article (PubMed ID: 36445254)
21. Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager.
Gripp KW; Baker L; Kandula V; Piatt J; Walter A; Chen Z; Messiaen L
Clin Genet; 2017 Nov; 92(5):540-543. PubMed ID: 28295212
[TBL] [Abstract][Full Text] [Related]
22. The integrated landscape of driver genomic alterations in glioblastoma.
Frattini V; Trifonov V; Chan JM; Castano A; Lia M; Abate F; Keir ST; Ji AX; Zoppoli P; Niola F; Danussi C; Dolgalev I; Porrati P; Pellegatta S; Heguy A; Gupta G; Pisapia DJ; Canoll P; Bruce JN; McLendon RE; Yan H; Aldape K; Finocchiaro G; Mikkelsen T; Privé GG; Bigner DD; Lasorella A; Rabadan R; Iavarone A
Nat Genet; 2013 Oct; 45(10):1141-9. PubMed ID: 23917401
[TBL] [Abstract][Full Text] [Related]
23. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
24. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
[TBL] [Abstract][Full Text] [Related]
25. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha A; Belugali Nataraj N; Lee JS; Zhitomirsky B; Oren Y; Oster S; Lindzen M; Mukherjee S; Will R; Ghosh S; Simoni-Nieves A; Verma A; Chatterjee R; Borgoni S; Robinson W; Sinha S; Brandis A; Kerr DL; Wu W; Sekar A; Giri S; Chung Y; Drago-Garcia D; Danysh BP; Lauriola M; Fiorentino M; Ardizzoni A; Oren M; Blakely CM; Ezike J; Wiemann S; Parida L; Bivona TG; Aqeilan RI; Brugge JS; Regev A; Getz G; Ruppin E; Yarden Y
Cancer Discov; 2022 Nov; 12(11):2666-2683. PubMed ID: 35895872
[TBL] [Abstract][Full Text] [Related]
26. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
27. High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Yoshimura A; Yamada T; Serizawa M; Uehara H; Tanimura K; Okuma Y; Fukuda A; Watanabe S; Nishioka N; Takeda T; Chihara Y; Takemoto S; Harada T; Hiranuma O; Shirai Y; Shukuya T; Nishiyama A; Goto Y; Shiotsu S; Kunimasa K; Morimoto K; Katayama Y; Suda K; Mitsudomi T; Yano S; Kenmotsu H; Takahashi T; Takayama K
Cancer Sci; 2023 Feb; 114(2):606-618. PubMed ID: 36169649
[TBL] [Abstract][Full Text] [Related]
28. Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
Chen S; Vedula RS; Cuevas-Navarro A; Lu B; Hogg SJ; Wang E; Benbarche S; Knorr K; Kim WJ; Stanley RF; Cho H; Erickson C; Singer M; Cui D; Tittley S; Durham BH; Pavletich TS; Fiala E; Walsh MF; Inoue D; Monette S; Taylor J; Rosen N; McCormick F; Lindsley RC; Castel P; Abdel-Wahab O
Cancer Discov; 2022 Oct; 12(10):2434-2453. PubMed ID: 35904492
[TBL] [Abstract][Full Text] [Related]
29. LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.
Abe T; Umeki I; Kanno SI; Inoue SI; Niihori T; Aoki Y
Cell Death Differ; 2020 Mar; 27(3):1023-1035. PubMed ID: 31337872
[TBL] [Abstract][Full Text] [Related]
30. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
31. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Mansouri S; Suppiah S; Mamatjan Y; Paganini I; Liu JC; Karimi S; Patil V; Nassiri F; Singh O; Sundaravadanam Y; Rath P; Sestini R; Gensini F; Agnihotri S; Blakeley J; Ostrow K; Largaespada D; Plotkin SR; Stemmer-Rachamimov A; Ferrer MM; Pugh TJ; Aldape KD; Papi L; Zadeh G
Acta Neuropathol; 2021 Jan; 141(1):101-116. PubMed ID: 33025139
[TBL] [Abstract][Full Text] [Related]
32. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
33. Typical 22q11.2 deletion syndrome appears to confer a reduced risk of schwannoma.
Evans DG; Messiaen LM; Foulkes WD; Irving REA; Murray AJ; Perez-Becerril C; Rivera B; McDonald-McGinn DM; Stevenson DA; Smith MJ
Genet Med; 2021 Sep; 23(9):1779-1782. PubMed ID: 33879870
[TBL] [Abstract][Full Text] [Related]
34. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
35. Structural Model for Recruitment of RIT1 to the LZTR1 E3 Ligase: Evidences from an Integrated Computational Approach.
Paladino A; D'Angelo F; Noviello TMR; Iavarone A; Ceccarelli M
J Chem Inf Model; 2021 Apr; 61(4):1875-1888. PubMed ID: 33792302
[TBL] [Abstract][Full Text] [Related]
36. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
[TBL] [Abstract][Full Text] [Related]
37. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous Detection of
Bianchessi D; Ibba MC; Saletti V; Blasa S; Langella T; Paterra R; Cagnoli GA; Melloni G; Scuvera G; Natacci F; Cesaretti C; Finocchiaro G; Eoli M
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32575496
[TBL] [Abstract][Full Text] [Related]
39. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
40. LZTR1 deficiency exerts high metastatic potential by enhancing sensitivity to EMT induction and controlling KLHL12-mediated collagen secretion.
Abe T; Kanno SI; Niihori T; Terao M; Takada S; Aoki Y
Cell Death Dis; 2023 Aug; 14(8):556. PubMed ID: 37626065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
